Avelumab in G2-3 NET
This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.
Neuroendocrine Tumors
DRUG: Avelumab
Overall response rate (ORR), The overall response rate will be defined as the number of participants with confirmed complete response or partial response (CR or PR) recorded as the best response over the study period, divided by the number of participants evaluable for response as defined by RECIST version 1.1., Up to 2 years
Disease control rate (DCR), The DCR will be defined as the number of patients with confirmed CR, PR or stable disease (SD) recorded as the best response over the study period, divided by the number of participants evaluable for response as defined by RECIST version 1.1., Up to 2 years|Duration of response, Time from documentation of tumour response to disease progression, Up to 2 years|Progression-free survival (PFS), PFS is defined as the time from first administration of study drug to the date of documented confirmed progression or death, whichever comes first, Up to 2 years|Overall survival (OS), OS is defined as the time from first administration of drug to date of death., Up to 2 years|Rates of treatment-emergent adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03, Up to 90 days after the last dose is administered|ORR by irRECIST version 1.1, Up to 2 years|DCR by irRECIST version 1.1, Up to 2 years|Duration of response by irRECIST version 1.1, Up to 2 years|PFS by irRECIST version 1.1, Up to 2 years|OS at 1 year, 1 year|OS at 2 years, 2 years|PFS at 1 year, 1 year|PFS at 2 years, 2 years
Correlation of PD-L1 status with response to avelumab, Up to 2 years|Correlation of mutational load and T-cell repertoire analysis with response to avelumab, Up to 2 years
This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.